SciSparc shares are trading higher after the company announced it signed an Exclusive Patent License Agreement with Polyrizon for the out-licensing of its SCI-160 program for the treatment of pain.
Portfolio Pulse from Benzinga Newsdesk
SciSparc shares are trading higher following the announcement of an Exclusive Patent License Agreement with Polyrizon for the out-licensing of its SCI-160 program aimed at treating pain.
August 19, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc shares are trading higher after the company announced an Exclusive Patent License Agreement with Polyrizon for the out-licensing of its SCI-160 program for pain treatment.
The announcement of an Exclusive Patent License Agreement is a significant development for SciSparc, indicating potential future revenue streams and market expansion for its SCI-160 program. This positive news has led to a rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100